Dupilumab Use in Severe Epidermolysis Bullosa Simplex
- 1 April 2026
- journal article
- observation
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 162 (4) , 423
Abstract
This case report describes treatment with dupilumab in an infant patient with generalized severe epidermolysis bullosa simplex due to a pathogenic variant.Keywords
This publication has 6 references indexed in Scilit:
- Treatment of epidermolysis bullosa simplex with dupilumabThe Journal of Dermatology, 2023
- Generalized, severe epidermolysis bullosa simplex caused by a Keratin 5 p.E477K mutationPediatric Dermatology, 2019
- Epidermolysis bullosa simplex–generalized severe type due to keratin 5 p.Glu477Lys mutation: Genotype‐phenotype correlation and in silico modeling analysisPediatric Dermatology, 2018
- p.Glu477Lys mutation in keratin 5 is not necessarily mortal in generalized severe epidermolysis bullosa simplexThe Journal of Dermatology, 2018
- The p.Glu477Lys Mutation in Keratin 5 Is Strongly Associated with Mortality in Generalized Severe Epidermolysis Bullosa SimplexJournal of Investigative Dermatology, 2016
- Primers for Exon-Specific Amplification of the KRT5 Gene: Identification of Novel and Recurrent Mutations in Epidermolysis Bullosa Simplex PatientsJournal of Investigative Dermatology, 1997